Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The pharmaceutical industry is undergoing a significant transformation - shifting away from the development of blockbuster drugs to a more value-driven approach based, increasingly, on specialty medicines for niche markets and patient outcomes. For the commercial operations landscape, specialty medicines come with their own specific challenges across data integration and data coverage. Further, ...

Incentive Compensation (IC) is one the key drivers of sales force effectiveness. To properly administer a sales incentive program it is important to recognize that IC is a dynamic process that must regularly flex and adjust to marketplace and corporate challenges. As commercial operations teams adjust their plans to account for these conditions, they must also strike a balance to ensure their ...

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines that use new scientific drug delivery systems, e.g., large molecules as opposed to traditional small molecule drugs, catering to smaller patient populations. While this shift solves some problems pharma has been facing, ...

The question this white paper addresses is straightforward – will COVID-19 call for restructuring the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE model has been a go-to metric for sales response modeling, sales force optimization, and sales operations analyses for 20+ years. However, with the implications of COVID-19 on the global healthcare ...

The question this commentary asks is simply this - has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceutical companies to the point that they now may well stifle the very innovative environment needed by companies to meet the scientific demands and expectations of society? The answer to this question leads to understanding how ...

The movement toward measuring patient outcomes resulting from a specific drug therapy, especially in an environment increasingly focused on specialty medicines, has caused researchers to look at different datasets than previously analyzed. Two patient-based datasets in particular come to mind: 1.) electronic health records (EHR), and 2.) claims data. These two data sources will each be suited to ...

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about the sustainability of increasing sales revenue mainly through pricing. Further, given the cost of newer specialty medicines, performance-based pharmaceutical pricing contracts through payers will become the norm. The ...

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind squirrel? This approach, while getting lucky a few times, is a poor recipe for sustained business success given the highly complex life sciences environment that now confronts senior executives and operational leaders. ...

There is a growing importance of maintaining sales rep-physician relationships and accounting for their disruption in sales force optimization and territory alignment analyses. This will become even more crucial as the industry increasingly moves toward launching specialty medicines and major changes occur in the environmental landscape affecting pharma outcomes in sales force strategy and ...